Pherecydes Pharma Overview

  • Founded
  • 2006
Founded
  • Status
  • Public
  • Employees
  • 30
Employees
  • Stock Symbol
  • ALPHE
Stock Symbol
  • Share Price
  • $5.38
  • (As of Monday Closing)

Pherecydes Pharma General Information

Description

Pherecydes Pharma develops phage-based therapeutic solutions for the treatment of bacterial infections. It focuses on various bacterial infections, including antibiotic-resistant infections, using phages, natural predators of bacteria that have no effect on eukaryotic cells, including human cells.

Contact Information

Website
www.pherecydes-pharma.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
PAR
Primary Office
  • 20 Boulevard Bénoni Goullin
  • 44200 Nantes
  • France
+33 01 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Pherecydes Pharma Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.38 $5.81 $5.38 - $11.22 $33.9M 5.84M 2.9K

Pherecydes Pharma Financials Summary

In Thousands,
USD 		TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
Revenue 1,553 2,531 109 360
EBITDA (3,715) (2,747) (3,692) (2,167)
Net Income (2,453) (1,368) (2,855) (1,729)
Total Assets 6,844 7,837 7,044 10,383
Total Debt 1 1,342 929 90
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pherecydes Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pherecydes Pharma‘s full profile, request access.

Request a free trial

Pherecydes Pharma Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Pherecydes Pharma‘s full profile, request access.

Request a free trial

Pherecydes Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Pherecydes Pharma develops phage-based therapeutic solutions for the treatment of bacterial infections. It focuses on va
Drug Discovery
Nantes, France
30 As of 2022
000.00
00.00 0000-00-00
00000000 000.00

00000

quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000 000000000
Ness Ziona, Israel
000 As of 0000
00000
000000000 00000

0000000

at nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserun
0000 000000000
Cambridge, MA
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pherecydes Pharma Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BiomX Formerly VC-backed Ness Ziona, Israel 000 00000 000000000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 000 00000 00000000000 00000
00000000 Venture Capital-Backed Cambridge, MA 000.00 0000000000 0 000.00
00000 00000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
00000 000000000 Venture Capital-Backed Cambridge, MA 00 0000 00000000000 0000
You’re viewing 5 of 17 competitors. Get the full list »

Pherecydes Pharma Patents

  • 79

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 6

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Pherecydes Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2020510024-A Phage therapy Pending 08-Mar-2017 000000000
EP-3592150-A1 Phage therapy Pending 08-Mar-2017 000000000
EP-3372085-A1 Phage therapy Withdrawn 08-Mar-2017 000000000 0
CA-3054874-A1 Phage therapy Pending 08-Mar-2017 000000000
AU-2018231408-A1 Phage therapy Pending 08-Mar-2017 A61K35/76
To view Pherecydes Pharma’s complete patent history, request access »

Pherecydes Pharma Executive Team (7)

Name Title Board Seat Contact Info
Guy-Charles de La Horie Chief Executive Officer & Chairman
Philippe Rousseau Chief Operating Officer, Chief Financial Officer & Board Member
Cindy Fevre Ph.D Chief Scientific Officer
You’re viewing 3 of 7 executive team members. Get the full list »

Pherecydes Pharma Board Members (11)

Name Representing Role Since
Claire Poulard Omnes Capital Supervisory Board Member 000 0000
Didier Hoch Self Chairman of Supervisory Board 000 0000
Eric Leire MD Self Supervisory Board Member 000 0000
Franck Lescure Ph.D Auriga Partners (Paris) Supervisory Board Member 000 0000
Guy Rigaud Self Supervisory Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Pherecydes Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial